Sanofi is to acquire Synthorx, a biotechnology company focused on improving the lives of people suffering from cancer and autoimmune diseases, for $2.5 billion.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 December 2019 Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
9 December 2019 Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
9 December 2019 Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
